Glucotrack to Participate in the Q3 Virtual Investor Summit
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes technologies, has announced its participation in the upcoming Q3 Virtual Investor Summit. Paul V. Goode, PhD, the company's President and CEO, will lead the presentation on Tuesday, September 16, 2025, at 1:30 PM ET.
The event will include a company presentation and one-on-one meetings with investors, providing an opportunity for stakeholders to learn more about Glucotrack's developments in diabetes technology.
Positive
- None.
Negative
- None.
News Market Reaction 50 Alerts
On the day this news was published, GCTK gained 5.18%, reflecting a notable positive market reaction. Argus tracked a peak move of +152.8% during that session. Our momentum scanner triggered 50 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $605K to the company's valuation, bringing the market cap to $12M at that time. Trading volume was exceptionally heavy at 144.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025.
Presentation details
Presenter: Paul V. Goode, PhD, President and Chief Executive Officer
Date: Tuesday, September 16, 2025
Time: 1:30PM ET
Webcast Link: Investor Summit Group Q3 Virtual Conference / Glucotrack
Investor registration: Investor Summit Group
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
| Contacts: Investor Relations: investors@glucotrack.com | Media: GlucotrackPR@icrinc.com |
FAQ
When is Glucotrack (GCTK) presenting at the Q3 Virtual Investor Summit?
Who will be presenting for Glucotrack at the Q3 Virtual Investor Summit?
What type of meetings will Glucotrack (GCTK) participate in during the Investor Summit?
How can investors register for Glucotrack's Q3 Virtual Investor Summit presentation?
